ClinicalTrials.gg
RecruitingNCT07557303Updated Sep 22, 2026

Supporting Just-In-Time Consent for Prenatal Screening: The INFORM Study

An interventional study of Mobile-based Educational Intervention in Delivery of Health Care, Genetic Testing and Humans, sponsored by Case Western Reserve University. Recruiting at 3 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Case Western Reserve University · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
1,400
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This clinical trial is about prenatal genetic screening. It will test an intervention to help people make decisions about screening. The intervention is a short set of information cards about screening. This intervention is for pregnant participants. They will use the intervention on their mobile phone before they see their doctor.

The study has one main question:

  • Do participants who use the intervention feel more confident when they make a decision about screening?

Researchers will compare participants who use the intervention to participants who do not. All participants will have their usual care when they visit their doctor.

What will participants do?

  • Participants must be pregnant. They will sign up for the study before their first doctor's visit for their pregnancy. This is the visit where their doctor usually talks with them about screening.
  • Some participants will use the intervention before their first doctor's visit. Other participants will not use it.
  • All participants will talk with a researcher on the phone after their first doctor's visit.
  • Participants who use the intervention will answer a short survey on their phone.
  • A few participants who use the intervention will talk with a researcher a second time on the phone.
02

Conditions studied

  • Delivery of Health Care
  • Genetic Testing
  • Humans
  • Pregnancy
  • Noninvasive Prenatal Testing
  • Informed Consent
  • Internet-Based Intervention
  • Self Efficacy
  • Pregnant People
  • Decision Making
  • Health Education
  • Patient Education as Topic/Method

Browse trials for

Keywords

  • Non-invasive prenatal screening (NIPS)
  • Non-Invasive Prenatal Testing (NIPT)
  • Cell-free DNA (cfDNA)
  • Prenatal genetic screening
  • Informed consent
  • Decision making
  • Surveys and Questionnaires
  • Informed choice
  • Educational intervention
  • Decision Regret
  • Decision Satisfaction
03

In context

Health Education

481 studies on the registry are indexed under Health Education; 110 are open to participants now.

This study's planned enrollment of 1,400 is above the median of 132 across 450 interventional studies indexed under Health Education.

Browse Health Education studies →

Lead sponsor

Case Western Reserve University is the lead sponsor of 160 studies on the registry; 28 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 7 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently pregnant and receiving care at a participating collaborative site - University of North Carolina, Chapel Hill; Zuckerberg Chan San Francisco General Hospital; University of Florida Health, Jacksonville.
  • 18 years of age and older
  • Able to read, speak, and understand English or Spanish
  • Has not previously been offered prenatal genetic screening for the current pregnancy
  • 24 weeks (6 months) gestational age or less

Exclusion criteria

Exclusion Criteria:

  • Not pregnant, not a patient at a partner clinical site
  • Younger than 18 years of age
  • Not being able to read, speak, and understand English or Spanish
  • Has previously been offered prenatal genetic screening for the current pregnancy
  • Greater than 24 weeks gestational age (6 months)
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,400 participants (estimated)

Study arms

  • Experimental
    Mobile-based Educational Intervention

    Participants in the intervention arm will access a mobile-based educational tool that provides concise, culturally appropriate information about prenatal genetic screening prior to their clinical visit. Immediately after viewing the intervention, participants will complete an online, 6-question acceptability survey. Participants will then complete a one-time structured quantitative telephone interview within one hundred sixty-eight hours (seven days) of their clinician visit to assess their experience with the intervention and to measure decisional self-efficacy. A select subset of participants will participate in an additional qualitative telephone interview to assess the efficacy and usability of the intervention.

    Behavioral: Mobile-based Educational Intervention

  • No intervention
    Standard of Care

    Participants in the standard-of-care arm will receive routine clinical care, including the usual information and counseling provided by clinicians regarding prenatal genetic screening. Participants will complete a one-time structured quantitative telephone interview within one hundred sixty-eight hours (seven days) of their clinician visit to assess their experience being offered prenatal genetic screening and measure decisional self-efficacy.

Interventions

  • BehavioralMobile-based Educational Intervention

    A mobile-based informational tool that participants will access through a Quick Response (QR) code prior to the clinical encounter in which they will be offered prenatal genetic screening. This tool will provide clear and concise information about prenatal genetic screening to support pregnant participants in making an informed decision.

06

What researchers measure

Primary outcomes

  1. Decision Self-Efficacy

    Decision self-efficacy is measured using a slightly adapted version of the "Decision Self-Efficacy Scale" developed by A. O'Connor and colleagues at the Ottawa Hospital Research Institute and is available at https://decisionaid.ohri.ca. The scale contains eleven questions about a patient's decision-making process. The scale was adapted to ask questions about the context of prenatal genetic screening and utilizes a three-point response scale. Response choices and corresponding point values are: "A lot confident (4), a little confident (2), and not confident (0)". The values from each response are summed, divided by 11 and multiplied by 100 to give a score range from 0 to 100. Zero indicates no confidence and 100 indicates extreme confidence. A researcher administers the scale over the phone, once to each participant, within 168-hours after the medical appointment where participants are offered prenatal genetic screening. It should take no more than 5-10 minutes to complete.

    Time frame: The scale is completed up to 168-hours (7 calendar days) post-prenatal screening visit.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Allyse MA, Sengupta S, Michie M. The Challenges of Reproductive Autonomy in an Unjust System. Am J Bioeth. 2025 Dec;25(12):67-69. doi: 10.1080/15265161.2025.2570681. Epub 2025 Nov 18. No abstract available. PubMed 41252505 ↗
  • Allyse M, Riggan K, Bonhomme N, Michie M. Rethinking the Burden of Traditional Informed Consent Prior to Prenatal Genetic Screening. Hastings Cent Rep. 2025 Mar;55(2):29-38. doi: 10.1002/hast.4976. PubMed 40245273 ↗

Individual participant data

Plan to share: Yes — Data will be shared via the Inter-university Consortium for Political and Social Research. To the extent the context of data collection can be revealed without compromising the privacy and identity of research participants, it will be included in study protocols. Data will be anonymized. Qualitative data such as de-identified and redacted transcripts, coding summaries, and metadata will be shared. Quantitative, including de-identified individual and aggregate survey data (including raw and recoded data) will be shared.

Supporting information: Statistical analysis plan, Informed consent form

Time frame: Approximately six to twelve months after the completion of data analysis. Methods and data collection instruments will be available to the research community before the completion of the study. Published outcomes as well as data deposited in the Inter-university Consortium for Political and Social Research will be available indefinitely.

Access criteria: Access to all deposited materials will be available to researchers registered and verified through the Inter-university Consortium for Political and Social Research (ICPSR). The ICPSR, a digital repository, utilizes a "Reference Model for an Open Archival Information System (OAIS), an International Organization for Standardization (ISO) standard that provides the functional framework for sustaining digital objects in managed repositories." Detailed access criteria can be found here: https://www.icpsr.umich.edu/sites/icpsr/about/policies/access-policy-framework

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2028, 21 months after the start.

Of 292 non-industry interventional studies with no phase under Health Education, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 21 months is above that.

Counting every sponsor, half of 293 studies reached it within 11 months; a quarter within 3 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 29, 2026
StartActual
Sep 10, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07557303
Responsible party
Marsha Michie (Associate Director, Department of Bioethics, Bioethics Center for Community Health ANd Genomic Equity (CHANGE), School of Medicine, Case Western Reserve University) — Principal investigator
First posted
Apr 29, 2026
Start date
Sep 10, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Sep 22, 2026

Study contacts

Sabina Rubeck, MPH
Contact
sabina.rubeck@case.edu
216-368-2547
Harlie Custer, MA, MPH
Contact
harlie.custer@case.edu
(216) 368-5914
Marsha Michie, PhD
principal investigator · Case Western Reserve University
Megan Allyse, PhD
principal investigator · Case Western Reserve University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion